Search the Newsreel

Pfizer Stock Forecast: 15% Upside as Its Pipeline Delivers New Wins

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial

Pfizer has announced positive topline data from two Phase 3 clinical trials for LITFULO, its once-daily treatment for nonsegmental vitiligo (NSV). The trials showed significant improvements in skin repigmentation, leading Pfizer to prepare global regulatory submissions for the drug. LITFULO, previously approved for severe …

Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer announced that its oral drug Litfulo successfully restored skin pigmentation in patients with nonsegmental vitiligo during two late-stage trials. The drug significantly improved facial and total-body repigmentation, paving the way for global regulatory submissions. Litfulo, which blocks specific immune cell proteins, is already …

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Pfizer announced positive topline results from two Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating LITFULO (ritlecitinib) for nonsegmental vitiligo (NSV). The studies demonstrated significant improvements in facial and total body repigmentation compared to placebo, meeting their co-primary endpoints. Based on these findings, Pfizer …

Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma

This article analyzes Pfizer (PFE) and Eli Lilly (LLY) as contrasting investment opportunities within the pharmaceutical sector. Pfizer is presented as a value and income play due to its low valuation and high dividend yield, despite challenges like declining COVID-19 product sales and patent …

Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. European Commission grants marketing authorization for Pfizer and BioNTech's XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in …

EU Approves Pfizer, BioNTech XFG COVID-19 Vaccine

The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine, targeting the XFG variant, for individuals aged 6 months and older. This approval follows the EMA's recommendation to update vaccines to better protect against the XFG variant of the JN.1 …

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping …

EU Authorizes Pfizer-BioNTech COVID Vaccine for Ages 6 Months+

The European Commission has granted marketing authorization for Pfizer and BioNTech's 2026-2027 monovalent XFG-adapted COVID-19 vaccine for individuals aged 6 months and older. This authorization, valid across 30 European countries, follows recommendations to target the XFG variant and is supported by data showing strong …

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer PFE is set to report its second-quarter 2026 earnings on Aug. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $14.45 billion and 68 cents per share, respectively. Estimates for Pfizer's 2026 earnings …

Pfizer's PREVNAR 20™ Selected for Québec's Publicly Funded Pediatric Pneumococcal Immunization Program

Pfizer's PREVNAR 20™, a 20-valent pneumococcal conjugate vaccine, has been chosen for Québec's publicly funded pediatric immunization program, making it the second Canadian province to adopt it. This initiative aims to provide broader serotype coverage against severe pneumococcal disease in infants and children. Healthcare …

Pfizer Number of Employees 2026 | Employee Count & Headcount Data

Pfizer Inc. had approximately 75,157 employees worldwide as of March 2026, marking an 8.3% decline from 2023. Despite the overall headcount reduction, Pfizer is actively hiring, with 2,887 active job postings in 2026, a 49.7% increase from the previous year. The company's workforce is …

Pfizer (PFE): Company Profile, Stock Price, News, Rankings

This article provides a company profile for Pfizer (PFE), detailing its business in developing medications and vaccines across various therapeutic areas, with a significant focus on oncology. It highlights key strategic moves such as the acquisition of Seagen and re-entry into the obesity market, …

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer (PFE) closed up 2.35% at $25.25, outperforming the S&P 500. Investors are anticipating the company's Q3 earnings report on August 4, 2026, with analysts expecting a 12.82% year-over-year decline in earnings per share and a 1.39% decrease in revenue. The stock currently holds …

Pfizer (NYSE:PFE) Shares Gain Pre-Earnings as 7% Dividend Undergoes Cash-Flow Scrutiny

Pfizer (NYSE:PFE) stock saw a modest gain ahead of its Q2 earnings report, as investors scrutinize the sustainability of its nearly 7% dividend amidst cash flow pressures. Preliminary consensus estimates project a decline in second-quarter earnings per share compared to the previous year, and …

Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026

As the industry prepares to gather in Boston this August, leaders from Gilead Sciences, GSK, and Pfizer will headline a plenary session exploring how AI and digital technologies are reshaping biopharmaceutical quality. BOSTON, July 28, 2026 /PRNewswire/ -- As the biopharmaceutical industry prepares to …

PFIZER: Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs

Pfizer reported higher revenue and net profit in Q1 FY27, with EPS increasing to ₹44.69. The company maintained a strong equity position despite exceptional costs in FY26 due to a Cipla agreement and labor code changes. This information is based on an interim report …

PFE|Pfizer Inc|Price:24.660|Chg%:+0.120

This article provides a comprehensive overview of Pfizer Inc. (PFE), detailing its current stock performance, key financial figures, and analyst ratings. It highlights the company's strong fundamentals and high growth potential within the pharmaceuticals industry, noting that its valuation is considered fairly valued. The …

Pfizer shares may move 3% around Aug. 4 earnings release By Investing.com

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Pfizer shares may move 3% around Aug. 4 earnings release

OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ...

This article first appeared on GuruFocus. Cash Position: Over $300 million in cash, cash equivalents, and restricted cash. Share Repurchase: 9.7 million shares repurchased for approximately $13 million. Diagnostics Revenue: $74.5 million in Q2 2026, including $6.2 million from 4Kscore test. Pharmaceutical Revenue: $89 …

Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer?

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. …

Quantinuum, NVIDIA Corporation, and Pfizer Inc Transformer Models Now Generate Quantum Circuits for Molecular Models

Researchers from Quantinuum, NVIDIA Corporation, and Pfizer Inc. have developed ADAPT-GQE, a generative AI framework that significantly speeds up the creation of quantum circuits for complex molecular modeling. This new approach reduces circuit generation time by an order of magnitude compared to ADAPT-VQE, while …

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Pfizer Japan Inc. and Eisai Co., Ltd. announced a co-promotion agreement for Nurtec® OD Tablet 75mg (rimegepant sulfate hydrate) in Japan, starting September 1, 2026. Nurtec is an oral CGRP receptor antagonist used for both acute treatment and prophylaxis of migraine. This collaboration aims …

Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?

Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. …

Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit.

This article discusses a patent dispute where Enanta Pharmaceuticals lost to Pfizer despite filing first, due to a single digit error in their provisional patent application. The Federal Circuit affirmed that Enanta's patent for a coronavirus protease inhibitor was invalid because the provisional application …

How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push

Pfizer's TALZENNA plus XTANDI combination drug for prostate cancer has received Priority Review from the FDA for a label expansion into earlier-stage treatment. This move aligns with Pfizer's strategy to focus on high-value oncology therapies as COVID-19 revenues decline and patent expirations loom. While …

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

Pfizer's high 7% dividend yield might seem unsustainable due to a high payout ratio, but the company's robust pipeline and strategic growth initiatives suggest its dividend program is more secure than it appears. Despite past revenue declines, new drug approvals like Padcev's expanded use …

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer PFE announced that the FDA has accepted the supplemental new drug application (sNDA) for Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), for an expanded use in prostate cancer. The sNDA is seeking approval …

Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access

Arkansas is suing 13 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Eli Lilly & Co., alleging they imposed unlawful restrictions on healthcare providers seeking drug discounts under the federal 340B Drug Pricing Program. Attorney General Tim Griffin claims these companies, along with their …

FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use

Pfizer Inc. announced that the FDA has accepted its supplemental New Drug Application for a Priority Review of TALZENNA in combination with XTANDI for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer. The FDA's Prescription Drug User Fee Act action date is …

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new …

Pfizer's prostate cancer drug combination gets US FDA priority review

Pfizer announced that the U.S. Food and Drug Administration has granted priority review for an expanded approval of its prostate cancer drug combination, Talzenna and Xtandi. This combination targets men with metastatic castration-sensitive prostate cancer who have HRR mutations. The FDA is expected to …

Pfizer trial: TALZENNA combo cut progression-or-death risk 52%

Pfizer announced that the FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA in combination with XTANDI for men with HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The sNDA is supported by Phase 3 TALAPRO-3 trial data showing the …